Feb 06, 2018
DUBLIN, Feb. 6, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today reported its fourth quarter and full-year 2017 continuing operations performance. Fourth Quarter and Full-Year 2017 Continuing Operations

(unaudited; $ in millions, except per share amounts) Q4 '17 Q4 '16 Q3 '17 Q4 '17 v Q4 '16 Q4 '17 v Q3 '17

Feb 06, 2018
DUBLIN, Feb. 6, 2018 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company today announced positive results from ACHIEVE I (UBR-MD-01), the first of two pivotal phase 3 clinical trials evaluating the efficacy, safety and tolerability of orally administered ubrogepant 50 mg and ubrogepant 100 mg compared to placebo in a single migraine attack in adults.
Feb 05, 2018
DUBLIN, Feb. 5, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) a leading global biopharmaceutical company, today announced that Matthew M. Walsh has been appointed Executive Vice President and Chief Financial Officer.  He will formally join Allergan later this month following a transition period from his current role as Executive Vice President, Chief Financial Officer at Catalent, Inc.
Feb 01, 2018
DUBLIN, Feb. 1, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Allergan's supplemental New Drug Application (sNDA) to expand the approved use of AVYCAZ® (ceftazidime and avibactam) to include the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by the following susceptible Gram-negative microorganisms: Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Serratia marcescens, Proteus mirabilis, Pseudomonas aeruginosa, and Haemophilus influenzae in patients 18 years of age or older. This expanded use is based on positive results from a pivotal Phase 3 study evaluating the efficacy and safety of AVYCAZ for the treatment of adult patients with HABP/VABP. The sNDA received priority review from FDA based on the Qualified Infectious Disease Product (QIDP) designation for the HABP/VABP indication.
Jan 31, 2018
DUBLIN, Jan. 31, 2018 /PRNewswire/ --  Allergan plc (NYSE:AGN), a leading global biopharmaceutical company, today announced that Chief Commercial Officer William Meury and Chief Research and Development Officer David Nicholson will present at the Leerink Partners 7th Annual Global Healthcare Conference in New York, NY. The presentation will begin at 10:00 a.m. Eastern Time on Thursday, February 15, 2018.
Jan 31, 2018
DUBLIN, Jan. 31, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today launches a new multi-channel direct-to-consumer campaign for CoolSculpting, titled "Not Cool vs. Cool," which includes a national traditional and digital media effort and two new brand ambassadors: figure skating superstar Johnny Weir and elite golfer Ian Poulter. CoolSculpting is the only FDA-cleared, non-surgical treatment to freeze away stubborn fat.
Jan 08, 2018
DUBLIN, Jan. 8, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, is providing its 2018 preliminary financial outlook and other financial updates at the 36th annual J.P. Morgan Healthcare Conference in San Francisco today. Commenting on the Company's 2018 outlook, Allergan Chairman and CEO Brent Saunders said, "While we face loss of exclusivity revenue headwinds in 2018, Allergan is in a solid position to unlock value in the near- and long-term. Our confidence is driven by the durable growth prospects for our businesses, the efforts we are taking to right-size the organization, our therapeutic area leadership, deep and high-potential pipeline and strong cash flows and balance sheet. Together, these elements provide a formidable foundation for Allergan to deliver value for shareholders in 2018 and beyond."
Jan 08, 2018
DUBLIN, Jan. 8, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it intends to release fourth quarter and full year 2017 financial results on Tuesday, February 6, 2018, prior to the open of U.S. Financial Markets. Allergan will host a conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, February 6, 2018 to discuss its financial results. The dial-in number to access the call is U.S./Canada (877) 251-7980, International (706) 643-1573, and the conference ID is 67779395.

You must be logged in to view this item.

This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.



The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?